Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Industry

Displaying 1 to 10 of 21 Posts . Displaying 10 of Posts . Page of 3 . Go To Page: . Per Page: . . . View All Sort By: .

Dermavant Announces FDA Approval for VTAMA® (Tapinarof) Cream

Dermavant announced the FDA approval for VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults. This is the first topical novel chemical entity launched for psoriasis in the U.S. in 25 years.

Read More

Bristol Myers Squibb (BMS) Announces New Two-Year Deucravacitinib Data

Bristol Myers Squibb (BMS) announced new two-year data that reinforces the durable efficacy and consistent safety profile of Deucravacitinib when used to treat moderate to severe plaque psoriasis.

Read More

New Corporate Member

IPC is pleased to welcome AnaptysBio as a Bronze Level Corporate Member!

Read More

Amgen announces new Otezla (apremilast) data

Amgen presents new data on the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis.

Read More

Janssen initiates first-of-its-kind clinical study to bridge critical gaps in care for people of color with moderate to severe plaque psoriasis

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color.

Read More

FDA approves second indication for SKYRIZI®

The U.S. Food and Drug Administration (FDA) has approved a second indication for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis.

Read More

New corporate member

IPC is pleased to welcome Arcutis Biotherapeutics, Inc. as a Bronze Level Corporate Member!

Read More

FDA approves Otezla® for treatment of plaque psoriasis

The FDA has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis.

Read More

FDA grants Priority Review for spesolimab

The FDA has granted priority review for spesolimab for the treatment of generalized pustular psoriasis flares.

Read More

European Commission approves SKYRIZI® for psoriatic arthritis in adults

The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults.

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

  


IPC STATEMENT
on SARS-CoV-2 Vaccines and Psoriasis
 

Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.

READ FULL STATEMENT


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK